NanoViricides, Inc. (NYSE American: NNVC) announced it has submitted an application to the Democratic Republic of Congo’s regulatory agency seeking approval to initiate a Phase II clinical trial of its NV-387 Oral Gummies for the treatment of the ongoing Bundibugyo ebolavirus outbreak. The company has retained Om Sai Clinical Research Private Limited as the contract research organization for the study, with drug supplies already positioned in the DRC. NV-387 is an orally administered broad-spectrum antiviral that targets host-side mechanisms viruses rely on to infect cells, an approach NanoViricides believes may reduce the likelihood of viral resistance.
The planned study builds on NanoViricides’ existing Phase II Mpox trial in the DRC and comes as the country grapples with an ebolavirus outbreak that, according to the company’s press release, has resulted in more than 930 deaths and nearly 2,400 confirmed cases since May. The company highlighted NV-387’s oral formulation, suggesting it could offer significant logistical advantages over infusion-based therapies in resource-limited settings. If successful, the drug could support the development of a broad-spectrum treatment for Ebola and other filoviruses.
NanoViricides is a clinical-stage company focused on creating special-purpose nanomaterials for antiviral therapy. Its lead drug candidate, NV-387, is being developed as a treatment for RSV, COVID-19, Long COVID, influenza, and other respiratory viral infections, as well as Mpox, smallpox, and measles. The company’s technology is based on intellectual property from TheraCour Pharma Inc., under a memorandum of understanding for developing drugs against all antiviral infections. For more details, the full press release is available at https://ibn.fm/tmrCX.
The DRC outbreak has underscored the urgent need for effective treatments against ebolaviruses, particularly in regions with limited healthcare infrastructure. NanoViricides’ oral gummy formulation could simplify administration compared to intravenous therapies, potentially improving patient compliance and enabling wider distribution. The company’s application to the DRC marks a critical step toward addressing this outbreak and advancing its clinical pipeline. Additional information about NanoViricides is available on its website at https://www.nanoviricides.com, and investors can find the latest news in the company’s newsroom at https://ibn.fm/NNVC.
This announcement matters because it represents a potential shift in how Ebola outbreaks are managed, moving from infusion-based treatments to more accessible oral options. If NV-387 proves effective, it could change the landscape of filovirus treatment and preparedness, offering a scalable solution for future outbreaks. The trial also highlights the importance of host-targeting antivirals in combating viral resistance, a growing concern in infectious disease management.
